WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
In a week during which 23andMe showed results from a clutch of its research programs at the American Society of Human Genetics annual meeting, it also tasked an industry veteran with winning new partnerships.
Physical therapy to help stroke patients regain hand motor function after a stroke is so highly repetitive that patients often struggle through it. Irvine,CA-based startup Flint Rehabilitation Devices has launched a device that could make that process more effective and less excruciating.
Eli Lilly is expanding its relationship with Canadian biotech Zymeworks, signing a broader deal that promises up to $375 million in milestones for its partner as the two collaborate on cancer immunotherapies.
Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.
Johnson & Johnson is expanding its network of biopharma incubators, taking to Texas with a plan to host as many as 50 local biotech startups.
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.
Fecal microbiota transplantation enables the reconstitution of gut bacteria, and has been proven effective to treat Clostridium difficile infections of the colon. But, as you can imagine, the nature of the active ingredient presents a tough drug delivery challenge. Luckily, the field is advancing.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.